Antioxidant supplements, genetics and chemotherapy outcomes
抗氧化剂补充剂、遗传学和化疗结果
基本信息
- 批准号:7284790
- 负责人:
- 金额:$ 59.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-06 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvant ChemotherapyAdjuvant StudyAdriamycin PFSAmericanAncillary StudyAntioxidantsApoptosisBlood specimenCancer PatientCaringCell DeathCellsClinical DataClinical ResearchClinical TrialsCohort EffectCyclophosphamideDNADataDatabasesDiagnostic Neoplasm StagingDietDiseaseDisease-Free SurvivalDoseEnrollmentFutureGSTP1 geneGenerationsGenesGeneticGenetic PolymorphismGenotypeGoalsGuidelinesInstitutesLeadLife StyleModificationNegative Axillary Lymph NodeNormal CellNumbersObservational StudyOutcomeOxidative StressPaclitaxelParentsPatientsPharmaceutical PreparationsPhasePhysical activityPhysiciansPopulation StudyPositive Lymph NodeProteinsRandomizedReactive Oxygen SpeciesRecommendationReportingResearchResearch DesignResearch PersonnelRiskRoleSouthwest Oncology GroupSpecimenSurveysTelephone InterviewsTestingTherapeuticTimeTodayToxic effectTreatment EfficacyTreatment ProtocolsTreatment outcomeTumor stageUpper armVariantVitaminsWomananticancer researchbasecancer cellcancer recurrencecell injurycell killingchemotherapeutic agentchemotherapycytotoxicdietary antioxidantglutathione S-transferase pimalignant breast neoplasmneoplastic cellprogramsresearch studysizesoundstatistical centertreatment trialtumor
项目摘要
DESCRIPTION (provided by applicant): Cancer patients report widespread use of antioxidant supplements during chemotherapy, despite the recommendations by the American Institute for Cancer Research and others that supplements not be used during treatment. These guidelines are based upon the fact that numerous chemotherapeutic agents, including those used to treat breast cancer, exert their cytotoxic effects by generation of reactive oxygen species (ROS), which cause massive damage to DNA and proteins and trigger apoptosis, resulting in tumor and normal cell death. Thus, there is the concern that antioxidants may block the ROS-generated effects of therapy on tumor cells. There are no data based on sound epidemiological or clinical studies to support this hypothesis, however. In fact, some experimental studies have shown that antioxidants may potentiate the effects of chemotherapeutic drugs, while also lessening treatment-related toxicities. We will investigate the question of whether or not use of antioxidant supplements during adjuvant chemotherapy has any impact on toxicities and disease-free, as well as overall, survival, and also evaluate the role of polymorphisms in genes related to oxidative stress in relation to treatment outcomes in the context of a newly activated Southwest Oncology Group (SWOG) clinical trial. In the ongoing Phase III Intergroup parent study chaired by SWOG, S0221, patients are randomized onto one of four arms that test different doses/intensities/intervals of cyclophosphamide, adriamycin, and paclitaxel. Blood specimens are being collected and banked. All patients upon enrollment in the treatment trial will be asked to be contacted for participation in this ancillary study. Telephone interviews will be conducted at the initiation of therapy, and at completion of treatment, regarding use of antioxidant supplements and other lifestyle factors. DNA will be genotyped for polymorphisms in a number of oxidative stress-related genes. Data will be analyzed at the SWOG Statistical Center, and supplement use and genetic variability will be evaluated in relation to toxicities, as well as to disease-free and overall survival. We will also explore the potential modification of antioxidant use on treatment outcomes by genetic variability. Because of the expected large size of this study, and the homogeneity of the study population and treatments given, the proposed study will have the capabilities to answer an extremely important question in the care of cancer patients today, and provide data that may lead to reduced treatment toxicities and increased disease-free survival.
描述(由申请人提供):尽管美国癌症研究所和其他机构建议在治疗期间不要使用补充剂,但癌症患者报告在化疗期间广泛使用抗氧化剂补充剂。这些指南基于以下事实:许多化疗药物,包括用于治疗乳腺癌的化疗药物,通过产生活性氧 (ROS) 发挥细胞毒性作用,对 DNA 和蛋白质造成大量损伤并引发细胞凋亡,导致肿瘤和癌症。正常的细胞死亡。因此,人们担心抗氧化剂可能会阻止 ROS 产生的肿瘤细胞治疗作用。然而,没有基于合理的流行病学或临床研究的数据来支持这一假设。事实上,一些实验研究表明,抗氧化剂可能会增强化疗药物的效果,同时还能减轻与治疗相关的毒性。我们将研究辅助化疗期间使用抗氧化剂补充剂是否对毒性和无病生存以及总体生存有影响的问题,并评估与氧化应激相关的基因多态性在治疗中的作用新启动的西南肿瘤学组 (SWOG) 临床试验的结果。在由 SWOG S0221 主持的正在进行的 III 期组间家长研究中,患者被随机分配到四个组中的一个,测试环磷酰胺、阿霉素和紫杉醇的不同剂量/强度/间隔。血液样本正在收集和储存。所有参加治疗试验的患者都将被要求联系以参与这项辅助研究。将在治疗开始和治疗完成时进行电话采访,内容涉及抗氧化剂补充剂的使用和其他生活方式因素。 DNA 将对许多氧化应激相关基因的多态性进行基因分型。数据将在 SWOG 统计中心进行分析,并将根据毒性以及无病生存率和总体生存率来评估补充剂的使用和遗传变异性。我们还将探讨遗传变异性对抗氧化剂的使用对治疗结果的潜在影响。由于这项研究的预期规模较大,以及研究人群和治疗方法的同质性,拟议的研究将有能力回答当今癌症患者护理中一个极其重要的问题,并提供可能导致减少癌症患者的数据。治疗毒性和增加无病生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christine B. Ambrosone其他文献
Christine B. Ambrosone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christine B. Ambrosone', 18)}}的其他基金
Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level.
非裔美国女性的产次、母乳喂养和 ER-乳腺癌之间的关系:阐明分子和细胞水平的生物学基础。
- 批准号:
10303040 - 财政年份:2018
- 资助金额:
$ 59.9万 - 项目类别:
Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level.
非裔美国女性的产次、母乳喂养和 ER-乳腺癌之间的关系:阐明分子和细胞水平的生物学基础。
- 批准号:
10057367 - 财政年份:2018
- 资助金额:
$ 59.9万 - 项目类别:
Relationships between parity, breastfeeding and ER- breast cancer in African American women: Elucidating the biologic underpinnings at the molecular and cellular level.
非裔美国女性的产次、母乳喂养和 ER-乳腺癌之间的关系:阐明分子和细胞水平的生物学基础。
- 批准号:
10520028 - 财政年份:2018
- 资助金额:
$ 59.9万 - 项目类别:
Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship
通路基础设施,乳腺癌存活率的前瞻性研究
- 批准号:
10622554 - 财政年份:2016
- 资助金额:
$ 59.9万 - 项目类别:
Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship
通路基础设施,乳腺癌存活率的前瞻性研究
- 批准号:
10439575 - 财政年份:2016
- 资助金额:
$ 59.9万 - 项目类别:
Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship
通路基础设施,乳腺癌存活率的前瞻性研究
- 批准号:
9044480 - 财政年份:2016
- 资助金额:
$ 59.9万 - 项目类别:
Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship
通路基础设施,乳腺癌存活率的前瞻性研究
- 批准号:
9980180 - 财政年份:2016
- 资助金额:
$ 59.9万 - 项目类别:
Infrastructure for Pathways, a Prospective Study of Breast Cancer Survivorship
通路基础设施,乳腺癌存活率的前瞻性研究
- 批准号:
10081095 - 财政年份:2016
- 资助金额:
$ 59.9万 - 项目类别:
Invasive breast cancer with and without DCIS: Race, risk factors and outcomes
伴或不伴 DCIS 的浸润性乳腺癌:种族、危险因素和结果
- 批准号:
8634076 - 财政年份:2013
- 资助金额:
$ 59.9万 - 项目类别:
Invasive breast cancer with and without DCIS: Race, risk factors and outcomes
伴或不伴 DCIS 的浸润性乳腺癌:种族、危险因素和结果
- 批准号:
8512328 - 财政年份:2013
- 资助金额:
$ 59.9万 - 项目类别:
相似国自然基金
弹性超声预测免疫调节型三阴性乳腺癌新辅助化疗联合免疫治疗的机制研究
- 批准号:82371978
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
多时序CT联合多区域数字病理早期预测胃癌新辅助化疗抵抗的研究
- 批准号:82360345
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
基于多时序CT影像与病理WSI智能预测局部进展期胃癌新辅助化疗疗效的研究
- 批准号:82371952
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于MRI-病理WSI-单细胞转录组测序多尺度信息的乳腺癌新辅助化疗腋窝淋巴结pCR智能预测及其生物学机制研究
- 批准号:82371933
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
新辅助化疗后CXCL12+CAF诱导胰腺癌三级淋巴结构表型特征与空间定位的分子机制研究
- 批准号:82373296
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC
项目2:PDAC新抗原疫苗耐药机制
- 批准号:
10708575 - 财政年份:2023
- 资助金额:
$ 59.9万 - 项目类别:
Targeting Tryptophan Metabolism in Rectal Cancer
靶向直肠癌中的色氨酸代谢
- 批准号:
10754178 - 财政年份:2023
- 资助金额:
$ 59.9万 - 项目类别:
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
新辅助来那替尼治疗 I-III 期 HER2 突变小叶乳腺癌
- 批准号:
10660734 - 财政年份:2023
- 资助金额:
$ 59.9万 - 项目类别:
Characterizing the immune infiltrate in muscle-invasive urothelial carcinoma
肌层浸润性尿路上皮癌免疫浸润的特征
- 批准号:
10738992 - 财政年份:2023
- 资助金额:
$ 59.9万 - 项目类别:
Integration of non-invasive deep tissue microwave thermometry in the VectRx hyperthermia device in a transgenic liver tumor pig model
在转基因肝肿瘤猪模型中将非侵入性深部组织微波测温技术集成到 VectRx 热疗装置中
- 批准号:
10697183 - 财政年份:2023
- 资助金额:
$ 59.9万 - 项目类别: